{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:48:18Z","timestamp":1769698098199,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.breast.2025.104519","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T19:14:34Z","timestamp":1749496474000},"page":"104519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Navigating discrepancies: The assessment of residual lymphovascular invasion in breast carcinoma after neoadjuvant treatment"],"prefix":"10.1016","volume":"82","author":[{"given":"Anik\u00f3","family":"Kov\u00e1cs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c5sa","family":"Rundgren-Sellei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunilla","family":"Rask","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bod\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"van Brakel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Col\u00f3n-Cervantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ehinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-4633","authenticated-orcid":false,"given":"Balazs","family":"Acs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.breast.2025.104519_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104519_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"9938","key":"10.1016\/j.breast.2025.104519_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"Pt 2","key":"10.1016\/j.breast.2025.104519_bib4","first-page":"215","article-title":"Tumor emboli in intramammary lymphatics in breast carcinoma: pathologic criteria for diagnosis and clinical significance","volume":"18","author":"Rosen","year":"1983","journal-title":"Pathol Annu"},{"issue":"3","key":"10.1016\/j.breast.2025.104519_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030968","article-title":"Updates on lymphovascular invasion in breast cancer","volume":"11","author":"Kuhn","year":"2023","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.breast.2025.104519_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100316","article-title":"Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study","volume":"6","author":"Houvenaeghel","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2025.104519_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1269971","article-title":"Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes","volume":"13","author":"Lee","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104519_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102923","article-title":"Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-na\u00efve patients with triple-negative breast cancer","volume":"9","author":"de Boo","year":"2024","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.breast.2025.104519_bib9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1349-7006.2009.01264.x","article-title":"Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy","volume":"100","author":"Tamura","year":"2009","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.breast.2025.104519_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-017-4610-0","article-title":"Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma","volume":"169","author":"Hamy","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.breast.2025.104519_bib11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10549-016-3837-5","article-title":"Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy","volume":"157","author":"Liu","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.breast.2025.104519_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/PAS.0000000000001029","article-title":"Pure intralymphatic invasion in the absence of stromal invasion after neoadjuvant therapy: a rare pattern of residual breast carcinoma","volume":"42","author":"Guilbert","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.breast.2025.104519_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/PAS.0000000000001610","article-title":"Postneoadjuvant pure and predominantly pure intralymphatic breast carcinoma: case series and literature review","volume":"45","author":"MacColl","year":"2021","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.breast.2025.104519_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/PAS.0b013e31817fbdb4","article-title":"Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease","volume":"33","author":"Rabban","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.breast.2025.104519_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234191","article-title":"Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: validation on a cohort of BC patients treated by neoadjuvant chemotherapy","volume":"15","author":"Hamy","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.breast.2025.104519_bib16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(17)30438-2","article-title":"The TNM classification of malignant tumours-towards common understanding and reasonable expectations","volume":"18","author":"O'Sullivan","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.breast.2025.104519_bib17","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.breast.2025.104519_bib18","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdv161","article-title":"Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration","volume":"26","author":"Bossuyt","year":"2015","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.breast.2025.104519_bib19","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104519_bib20","unstructured":"Bossuyt V., Provenzano E., Symmans W.F., et al. Invasive Carcinoma of the Breast in the Setting of Neoadjuvant Therapy Histopathology Reporting Guide. 2nd edition. Int Collab Cancer Report 2022. Sydney. ISBN: 978-1-922324-36."},{"issue":"5","key":"10.1016\/j.breast.2025.104519_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"10.1016\/j.breast.2025.104519_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4132\/jptm.2020.11.20","article-title":"Standardized pathology report for breast cancer","volume":"55","author":"Cho","year":"2021","journal-title":"J Pathology Transl Medicine"},{"issue":"4","key":"10.1016\/j.breast.2025.104519_bib23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/PAP.0000000000000237","article-title":"Evaluation of breast and axillary lymph node specimens in breast cancer patients treated with neoadjuvant systemic therapy","volume":"26","author":"Baker","year":"2019","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.breast.2025.104519_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2024.02.002","article-title":"Residual pure intralymphatic carcinoma component only (lymphovascular tumor emboli without invasive carcinoma) after neoadjuvant chemotherapy is associated with poor outcome: not pathologic complete response","volume":"145","author":"Lee","year":"2024","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.breast.2025.104519_bib25","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1097\/PAS.0000000000000896","article-title":"Residual pure intralymphatic breast carcinoma following neoadjuvant chemotherapy is indicative of poor clinical outcome, even in node-negative patients","volume":"41","author":"Cheng","year":"2017","journal-title":"Am J Surg Pathol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T03:09:15Z","timestamp":1769656155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625005363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"alternative-id":["S0960977625005363"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104519","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating discrepancies: The assessment of residual lymphovascular invasion in breast carcinoma after neoadjuvant treatment","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104519"}}